Viridian Therapeutics, Inc.

The Company has funded its operations to date principally through proceeds received from the sale of the Company s common stock, Series A convertible preferred stock, Series B convertible preferred stock, and other equity securities, debt financings, and license fees and reimbursements received under collaboration agreements.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

DEBT Convertible Notes In May 2026, the Company completed a public offering of $ 250.0 million aggregate principal amount of its 1.75 % convertible senior notes due 2032 (the Notes ), including the exercise in full of the underwriters option to purchase up to an additional $ 25.0 million aggregate principal amount of the Notes.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Notes will mature on May 15, 2032, unless earlier converted, redeemed or repurchased by the Company.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

As of June 30, 2026, the Notes are classified as a long-term liability on the condensed consolidated balance sheets and presented net of unamortized debt discount and issuance costs of $ 7.8 million.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Under the Hercules Loan and Security Agreement, the Lenders provided the Borrower with access to a term loan with an aggregate principal amount of up to $ 75.0 million, in four tranches, including an initial tranche of $ 25.0 million.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Hercules First Amendment was determined to substantially alter the Hercules Loan and Security Agreement and therefore was accounted for as a debt extinguishment.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2025.

SEC original ↗Viridian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We are making extraordinary progress on our commercial preparation and we plan to be launch-ready on a Priority Review designation timeline, if we receive it.

SEC original ↗Viridian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

BTD supports eligibility for Priority Review which, if received, could accelerate our timing for veli commercial launch.

SEC original ↗Viridian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases.

SEC original ↗Viridian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

, a Delaware corporation (the Company or Viridian ), is a biopharmaceutical company focused on discovering, developing and commercializing potentially best-in-class medicines for autoimmune and rare diseases.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

SEC original ↗Viridian Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 42 Item 1A.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Exhibits 85 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ( Quarterly Report ) contains forward-looking statements that involve risks and uncertainties.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Given these uncertainties, you should not place undue reliance on these forward-looking statements.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.

SEC original ↗Viridian Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026